Tocilizumab

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Giant Cell Arteritis

Conditions

Giant Cell Arteritis

Trial Timeline

Oct 25, 2017 → Aug 21, 2019

NCT ID

NCT03202368

About Tocilizumab

Tocilizumab is a phase 3 stage product being developed by Roche for Giant Cell Arteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03202368. Target conditions include Giant Cell Arteritis.

What happened to similar drugs?

5 of 13 similar drugs in Giant Cell Arteritis were approved

Approved (5) Terminated (3) Active (6)

🔄PexidartinibDaiichi SankyoPhase 3

✅PexidartinibDaiichi SankyoApproved

🔄Upadacitinib + Corticosteroid (CS)AbbViePhase 3

🔄Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.NovartisPhase 3

🔄Secukinumab 300 mg + Secukinumab 150 mgNovartisPhase 3

🔄Tocilizumab + PlaceboRochePhase 3

✅Tocilizumab + PrednisoneRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05164133	Phase 1	Completed	Jun 10, 2022	Mar 27, 2024	COVID-19
NCT04445272	Phase 2	Completed	May 22, 2020	Dec 23, 2020	COVID-19
NCT03923738	Phase 1	Completed	Aug 5, 2019	Nov 12, 2020	Giant Cell Arteritis
NCT03202368	Phase 3	Completed	Oct 25, 2017	Aug 21, 2019	Giant Cell Arteritis
NCT03046381	Phase 2	Completed	Jul 19, 2017	Apr 10, 2019	Schnitzler's Syndrome
NCT02648035	Pre-clinical	Completed	Sep 22, 2016	Dec 20, 2018	Rheumatoid Arthritis
NCT02682823	Approved	Completed	Mar 21, 2016	Jul 29, 2016	Rheumatoid Arthritis
NCT02678988	Phase 1	Completed	Feb 1, 2016	Jun 1, 2016	Healthy Volunteer
NCT02676947	Phase 2	Completed	Jan 1, 2016	Feb 18, 2018	Pulmonary Arterial Hypertension
NCT02552940	Pre-clinical	Completed	Oct 31, 2015	Oct 23, 2017	Rheumatoid Arthritis
NCT02534311	Pre-clinical	Completed	Oct 13, 2015	Dec 1, 2015	Rheumatoid Arthritis
NCT02402686	Pre-clinical	Completed	May 20, 2015	Dec 17, 2018	Rheumatoid Arthritis
NCT02234960	Pre-clinical	Completed	Aug 1, 2014	Jul 1, 2016	Rheumatoid Arthritis
NCT02165345	Phase 1	Completed	Jul 16, 2014	Nov 24, 2021	Juvenile Idiopathic Arthritis
NCT02087696	Approved	UNKNOWN	May 1, 2014	Jul 1, 2016	Arthritis, Rheumatoid
NCT02031471	Phase 3	Completed	Jan 1, 2014	Sep 1, 2015	Rheumatoid Arthritis
NCT01988012	Phase 3	Completed	Jan 1, 2014	Jul 1, 2015	Rheumatoid Arthritis
NCT01668966	Phase 3	Completed	Dec 9, 2013	May 11, 2016	Rheumatoid Arthritis
NCT01951170	Phase 3	Completed	Nov 1, 2013	Aug 1, 2015	Rheumatoid Arthritis
NCT01904292	Phase 1	Completed	Aug 15, 2013	Jun 13, 2017	Juvenile Idiopathic Arthritis

Competing Products

20 competing products in Giant Cell Arteritis

See all competitors

Product	Company	Stage	Hype Score
prednisone	Kiniksa Pharmaceuticals	Phase 2	29
Pexidartinib	Daiichi Sankyo	Phase 2	39
Pexidartinib	Daiichi Sankyo	Phase 3	44
Pexidartinib	Daiichi Sankyo	Approved	43
Baricitinib	Eli Lilly	Phase 2	35
Upadacitinib + Corticosteroid (CS)	AbbVie	Phase 3	40
dovitinib	Novartis	Phase 2	35
Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.	Novartis	Phase 3	40
Secukinumab 300 mg, s.c. + Prednisolone + Placebo	Novartis	Phase 2	35
Secukinumab	Novartis	Phase 1	29
Secukinumab 300 mg + Secukinumab 150 mg	Novartis	Phase 3	40
Tocilizumab + Placebo	Roche	Phase 3	44
Tocilizumab + Prednisone	Roche	Approved	43
Tocilizumab	Roche	Phase 1	29
Valganciclovir	Roche	Approved	35
Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate	Roche	Phase 3	40
Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs)	Roche	Phase 2	35
tocilizumab and IV steroids combination	Roche	Phase 2	31
Denosumab	Amgen	Approved	43
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]	Amgen	Phase 2	27